Note: Descriptions are shown in the official language in which they were submitted.
CA 02296653 2003-08-27
TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE,
INSULIN SECRETAGOGUE AND BIGUANIDE
This invention relates to the treatment of diabetes mellitus, especially non-
insulin dependent diabetes (NIDDM) (or Type 2 diabetes) and conditions
associated
with diabetes mellitus.
Insulin secretagogues are compounds which proniote increased secretion of
insulin by the pancreatic beta cells.
The sulphonylureas are well known examples of insulin secretagogues. The
sulphonylureas act as antihyperglycaemic agents and are used in the treatment
of
Type 2 diabetes. Examples of sulphonylureas include glibenclamide, glipizide,
gliclazide, glimepiride, tolazamide and tolbutamide.
Biguanide antihyperglycaemic agents are commonly used in the treatment of
Type 2 diabetes. 1, 1 -Dimethylbiguanidine (or Metformin) is an example of a
biguanide antihyperglycaemic agent.
European Patent Application, Publication Number 0,306,228 relates to
certain thiazolidinedione derivatives disclosed as having antihyperglycaemic
and
antihyperlipidaemic activity. One particular thiazolidinedione disclosed in EP
0306228 is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-
dione (hereinafter "Compound (I)"). WO 94/05659 discloses certain salts of
Compound (I) including the maleate salt.
Compound (I) is an example of a class of anti-hyperglycaemic agents known
as "insulin sensitisers". In particular Compound (I) is a thiazolidinedione
insulin
sensitiser.
European Patent Applications, Publication Numbers 0008203, 0139421,
0032128, 0428312, 0489663, 0155845, 0257781, 0208420, 0177353, 0319189,
0332331, 0332332, 0528734, 0508740; International Patent Application,
Publication
Numbers 92/18501, 93/02079, 93/22445 and United States Patent Numbers
5104888 and 5478852, also disclose certain thiazolidinedione insulin
sensitisers.
1
CA 02296653 2005-10-13
It is now surprisingly indicated that a specific dosage of Compound (I) or a
tautomeric form thereof and/or a pharmaceutically acceptable derivative
thereof in
combination with glimepiride and a biguanide antihyperglycaemic agent provides
a
particularly beneficial effect on glycaemic control. Such a combination is
therefore
particularly useful for the treatment of diabetes mellitus, especially Type 2
diabetes and
conditions associated with diabetes mellitus. The treatment is also indicated
to proceed
with minimum side effects.
Accordingly, the invention provides a combination comprising 2 to 12mg of
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
(Compound
I) or a tautomeric form thereof and/or a pharmaceutically acceptable
derivative thereof ,
glimepiride and a biguanide antihyperglycaemic agent.
In the combination compound (I), or a tautomeric form thereof and/or a
pharmaceutically acceptable derivative thereof, the glimepiride and the
biguanide
antihyperglycaemic agent are formulated either as a single pharmaceutical
composition or
as separate pharmaceutical compositions.
In another aspect the invention provides the use of 2 to 12 mg of
5-[4-[2-(N-methyl)-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
(Compound 1) or a tautomeric form thereof and/or a pharmaceutically acceptable
derivative thereof, glimepiride and a biguanide antihyperglycaemic agent in
the
manufacture of a medicament for use in the treatment of diabetes mellitus
and/or a
condition associated with diabetes mellitus
In a further aspect the invention provides the use of 2 to 12 mg of
5-[4-[2-(N-methyl)-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
(Compound 1) or a tautomeric form thereof and/or a pharmaceutically acceptable
derivative thereof, in the manufacture of a medicament for use with
glimepiride and a
biguanide antihyperglycaemic agent in the treatment of diabetes mellitus
and/or a
condition associated with diabetes mellitus.
In a still further aspect the invention provides the use of glimepiride in the
manufacture of a medicament for use with 2 to 12 mg of
5-[4-[2-(N-methyl)-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
(Compound I) or a tautomeric form thereof and/or a pharmaceutically acceptable
derivative thereof, and a biguanide
-2-
. .~,~.......,~ ~. ,.. ~ . , , , , ~..~~, _ .
CA 02296653 2005-10-13
antihyperglycaemic agent in the treatment of diabetes mellitus and/or a
condition
associated with diabetes mellitus.
In yet another aspect the invention provides the use of a biguanide
antihyperglycaemic agent in the manufacture of a medicament for use with 2 to
12 mg of
5- [4- [2-(N-methyl)-N-(2-pyridyl) amino)
ethoxy]benzyl]thiazolidine-2,4-dione (Compound I) or a tautomeric form thereof
and/or a
pharmaceutically acceptable derivative thereof, and glimepiride in the
treatment of
diabetes mellitus and/or a condition associated with diabetes mellitus.
A suitable biguanide antihyperglycaemic agent is metformin, buformin or
phenformin, especially metformin.
In accordance with the invention 2 to 12 mg of Compound (I) or a tautomeric
form thereof and/or a pharmaceutically acceptable derivative thereof is
administered,
especially per day.
Particularly, the combination of the invention comprises 2 to 4, 4 to 8 or 8
to 12
mg of Compound (I) or a tautomeric form thereof and/or a pharmaceutically
acceptable
derivative thereof. Typically this dosage is given per day.
Particularly, the combination of the invention comprises 2 to 4 mg of Compound
(I) or a tautomeric form thereof and/or a pharmaceutically acceptable
derivative thereof.
Typically this dosage is given per day.
Particularly, the combination of the invention comprises 4 to 8 mg of Compound
(I) or a tautomeric form thereof and/or a pharmaceutically acceptable
derivative thereof.
Typically this dosage is given per day.
Particularly, the combination of the invention comprises 8 to 12 mg of
Compound
(I) or a tautomeric form thereof and/or a pharmaceutically acceptable
derivative thereof.
Typically this dosage is given per day.
Preferably, the combination of the invention comprises 2 mg of Compound (I) or
a tautomeric form thereof and/or a pharmaceutically acceptable derivative
thereof.
Typically this dosage is given per day.
Preferably, the combination of the invention comprises 4 mg of Compound (I) or
a tautomeric form thereof and/or a pharmaceutically acceptable derivative
thereof.
Typically this dosage is given per day.
-3-
CA 02296653 2005-10-13
Preferably, the combination of the invention comprises 8 mg of Compound (I) or
a tautomeric form thereof and/or a pharmaceutically acceptable derivative
thereof.
Typically this dosage is given per day.
It will be understood that compound (I), the glimepiride and the biguanide
antihyperglycaemic agent are each administered in a pharmaceutically
acceptable form,
including pharmaceutically acceptable derivatives such as pharmaceutically
acceptable
salts, esters and solvates thereof, as appropriate. In certain instances
herein the names
used for the biguanide antihyperglycaemic agents may relate to a particular
pharmaceutical form of the relevant active agent: It will be understood that
all
pharmaceutically acceptable forms of the active agents per se are encompassed
by this
invention.
Suitable pharmaceutically acceptable salted forms of Compound (I) include
those
described in the above mentioned patents and patent applications such as in EP
0306228
and WO 94/05659. A preferred pharmaceutically acceptable salt for Compound (I)
is a
maleate.
Suitable pharmaceutically acceptable solvated forms of Compound (I) include
those described in the above mentioned patents and patent applications, such
as in EP
0306228 and WO 94/05659, in particular hydrates.
Suitable pharmaceutically acceptable forms of the glimepiride and the
biguanide
antihyperglycaemic agent depend upon the particular compound used but include
known
pharmaceutically acceptable forms of the particular compound chosen. Such
derivatives
are found or are referred to in standard reference texts such as British and
US
Pharmacopoeias, Remington: The Science and Practice of Pharmacy (formerly
Remington's Pharmaceutical Sciences) 19th edition, 1995, Mack Publishing Co.,
Easton
PA., Martindale the Extra Pharmacopoeia (London, The Pharmaceutical Press)
(for
example see the 31st Edition, 1996, page 341 and pages cited therein).
Compound (I) or a pharmaceutically acceptable salt thereof, or a
pharmaceutically
acceptable solvate thereof, may be prepared using known methods, for example
those
disclosed in the above mentioned patents and patent applications, such as EP
0306228
and WO 94/05659.
-4-
CA 02296653 2005-10-13
Compound (I) may exist in one or several tautomeric forms, all of which are
encompassed by the term Compound (I) as individual tautomeric forms or as
mixtures
thereof. Compound (I) contains a chiral carbon atom, and hence can exist in up
to two
stereoisomeric forms, the term Compound (I) encompasses all of these isomeric
forms
whether as individual isomers or as mixtures of isomers, including racemates.
The glimepiride and biguanide antihyperglycaemic agent of choice is prepared
according to known methods, such methods are found or are referred to in
standard
reference texts, such as the British and US Pharmacopoeias, Remington (cited
above),
Martindale The Extra Pharmocopoeia (London, The Pharmaceutical Press) (for
example
see the 31 st Edition, 1996, page 341 and pages cited therein).
When used herein the term "conditions associated with diabetes" includes
conditions associated with diabetes mellitus itself and complications
associated with
diabetes mellitus. Also included in "conditions association with diabetes" are
those
conditions associated with the pre-diabetic state.
When used herein the term "conditions associated with pre-diabetic state"
includes conditions such as insulin resistance, including hereditary insulin
resistance,
impaired glucose tolerance and hyperinsulinaemia.
-5-
CA 02296653 2003-08-27
"Conditions associated with diabetes mellitus itself' include hyperglycaemia,
insulin resistance, including acquired insulin resistance. Further conditions
associated with diabetes mellitus itself include hypertension and
cardiovascular
disease, especially atherosclerosis and conditions associated with insulin
resistance.
Conditions associated with insulin resistance include polycystic ovarian
syndrome
and steroid induced insulin resistance and gestational diabetes.
"Complications associated with diabetes mellitus" includes renal disease,
especially renal disease associated with Type 2 diabetes, neuropathy and
retinopathy.
Renal diseases associated with Type 2 diabetes include nephropathy,
glomerulonephritis, glomerular sclerosis, hypertensive nephrosclerosis and end
stage
renal disease. Additional renal diseases associated with Type 2 diabetes
include
nephrotic syndrome.
For the avoidance of doubt, when reference is made herein to scalar amounts,
including mg amounts, of Compound (I) in a pharmaceutically acceptable form,
the
scalar amount referred to is made in respect of Compound (I) per se. For
example 2
mg of Compound (I) in the form of the maleate salt is that amount of maleate
salt
which contains 2 mg of Compound (I).
Diabetes mellitus is preferably Type 2 diabetes.
The particularly beneficial effect of glycaemic control provided by the
treatment of the invention is indicated to be a synergistic effect relative to
the control
expected for the sum of the effects of the individual active agents.
Suitably Compound (I) is the agent of first administration. Glycaemic control
may be characterised using conventional methods, for example by measurement of
a
typically used index of glycaemic control such as fasting plasma glucose or
glycosylated haemoglobin (HbAlc). Such indices are determined using standard
methology, for example those described in: Tuescher A, Richterich, P.,
Schweiz. med.
Wschr.101 (1971), 345 and 390 and Frank P., "Monitoring the Diabetic Patent
with
Glyscosolated Hemoglobin Measurements", Clinical Products 1988.
In a preferred aspect, the dosage level of each of the active agents when used
6
CA 02296653 2005-10-13
in accordance with the treatment of the invention will be less than would have
been
required from a purely additive effect upon glycaemic control.
There is also an indication that the treatment of the invention will effect an
improvement, relative to the individual agents, in the levels of advanced
glycosylation
end products (AGEs), leptin and serum lipids including total cholesterol,
HDL-cholesterol, LDL-cholesterol including improvements in the ratios thereof,
in
particular an improvement in serum lipids including total cholesterol, HDL-
cholesterol,
LDL-cholesterol including improvements in the ratios thereof.
As used herein the term "pharmaceutically acceptable" embraces both human and
veterinary use: for example the term "pharmaceutically acceptable" embraces a
veterinarily acceptable compound.
In the present invention, the active medicaments are preferably administered
in
pharmaceutical composition form. As indicated above, such compositions can
include all
medicaments or one only of the medicaments.
Accordingly, in one aspect of the invention also provides a pharmaceutical
composition comprising 2 to 12 mg of Compound (I) or a tautomeric form thereof
and/or
a pharmaceutically acceptable derivative thereof, glimepiride and a biguanide
antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor.
Such compositions may be prepared by admixing 2 to 12 mg of Compound (I) or
a tautomeric form thereof and/or a pharmaceutically acceptable derivative
thereof,
glimepiride and a biguanide antihyperglycaemic agent and a pharmaceutically
acceptable
carrier therefor.
Usually the compositions are adapted for oral administration. However, they
may
be adapted for other modes of administration, for example parenteral
administration,
sublingual or transdermal administration.
The compositions may be in the form of tablets, capsules, powders, granules,
lozenges, suppositories, reconstitutable powders, or liquid preparations, such
as oral or
sterile parenteral solutions or suspensions.
In order to obtain consistency of administration it is preferred that a
composition
of the invention is in the form of a unit dose.
Unit dose presentation forms for oral administration may be tablets
-6a-
CA 02296653 2005-10-13
and capsules and may contain conventional excipients such as binding agents,
for
example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone;
fillers, for
example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine;
tabletting
lubricants, for example magnesium stearate; disintegrants, for example starch,
polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose;
or
pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.
The compositions are preferably in a unit dosage form in an amount appropriate
for the relevant daily dosage.
Suitable dosages of Compound (I) comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12
mg
of Compound (I).
In the treatment the medicaments may be administered from 1 to 6 times a day,
but most preferably 1 or 2 times pr day.
Particular dosages of Compound (I) are 2 mg/day, 4 mg/day, including 2 mg
twice per day, and 8 mg/day, including 4 mg twice per day.
Suitable dosages including unit dosages of the insulin secretagogue, such
as the sulphonylurea or the biguanide antihyperglycaemic agent, include the
known
dosages including unit doses for these compounds as described or referred to
in reference
text such as the British and US Pharmacopoeias, Remington (cited above), and
Martindale, The Extra Pharmacopoeia (cited above).
For sulphonylureas generally, a typical daily dosage of glibenclamide is in
the
range of from 2.5 to 20 mg, for example 10 mg twice per day or 20 mg one per
day; a
-6b-
CA 02296653 2000-01-18
WO 99/03477 PCT/GB98/02110
typical daily dosage of glipizide is in the range of from 2.5 to 40 mg; a
typical daily
dosage of gliclazide is in the range of from 40 to 320 mg; a typical daily
dosage of
tolazamide is in the range of from 100 to 1000 mg; a typical daily dosage of
tolbutamide is in the range of from 1000 to 3000 mg; a typical daily dosage of
chlorpropamide is in the range of from 100 to 500 mg; and a typical daily
dosage of
gliquidone is in the range of from 15 to 180 mg.
Repaglinide may be taken in amounts, usually in the range of from 0.5mg to
4mg and usually with meals, up to a typical maximum daily dosage of 16mg per
day.
With regard to the biguanide antihyperglycaemic agents, suitable dosages of
metformin include up to 3000mg per day, in unit doses of 500mg (for example
two or
three times per day) or 850mg (for example two times per day), one example of
a
dosage for metformin is 500mg once building to five times per day.
The solid oral compositions may be prepared by conventional methods of
blending, filling or tabletting. Repeated blending operations may be used to
distribute
the active agent throughout those compositions employing large quantities of
fillers.
Such operations are of course conventional in the art. The tablets may be
coated
according to methods well known in normal pharmaceutical practice, in
particular
with an enteric coating.
Oral liquid preparations may be in the form of, for example, emulsions,
syrups, or elixirs, or may be presented as a dry product for reconstitution
with water
or other suitable vehicle before use. Such liquid preparations may contain
conventional additives such as suspending agents, for example sorbitol, syrup,
methyl
cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium
stearate
gel, hydrogenated edible fats; emulsifying agents, for example lecithin,
sorbitan
monooleate, or acacia; non-aqueous vehicles (which may include edible oils),
for
eYample almond oil, fractionated coconut oil, oily esters such as esters of
glycerine,
propylene glycol, or ethyl alcohol; preservatives, for example methyl or
propyl
p-hydroxvbenzoate or sorbic acid; and if desired conventional flavouring or
colouring
agents.
For parenteral administration, fluid unit dosage forms are prepared utilizing
the compound and a sterile vehicle, and, depending on the concentration used,
can be
either suspended or dissolved in the vehicle. In preparing solutions the
compound can
be dissolved in water for injection and filter sterilized before filling into
a suitable vial
or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic,
a
preservative and buffering agents can be dissolved in the vehicle. To enhance
the
stability, the composition can be frozen after filling into the vial and the
water
removed under vacuum. Parenteral suspensions are prepared in substantially the
same
manner, except that the Compound (I) is suspended in the vehicle instead of
being
-7-
CA 02296653 2005-10-13
dissolved, and sterilization cannot be accomplished by filtration. The
compound can be
sterilized by exposure to ethylene oxide before suspending in the sterile
vehicle.
Advantageously, a surfactant or wetting agent is included in the composition
to facilitate
uniform distribution of the compound.
Compositions may contain from 0.1% to 99% by weight, preferably from 10-60%
by weight, of the active material, depending upon the method of
administration.
Composition may, if desired, be in the form of a pack accompanied by written
or
printed instructions for use.
The compositions are prepared and formulated according to conventional
methods, such as those disclosed in standard reference texts, for example the
British and
US Pharmacopoeias, Remington (cited above), Martindale The Extra Pharmacopoeia
(London, The Pharmaceutical Press) (for example see the 31 St Edition page 341
and
pages cited therein) and Harry's Cosmeticology (Leonard Hill Books) for
instance 6th
Edition, 1973.
In particular, the present invention provides a pharmaceutical composition
comprising 2 to 12 mg of Compound (I) or a tautomeric form thereof and/or a
pharmaceutically acceptable derivative thereof, glimepiride and a biguanide
antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor,
for use in
the treatment of diabetes mellitus and conditions associated with diabetes
mellitus.
A range of 2 to 4 mg includes a range of 2.1 to 4, 2.2 to 4, 2.3 to 4, 2.4 to
4, 2.5 to
4,2.6to4,2.7to4,2.8to4,2.9to4or3to4.
A range of 4 to 8 mg includes a range of 4.1 to 8, 4.2 to 8, 4.3 to 8, 4.4 to
8, 4.5 to
8, 4.6 to 8, 4.7 to 8, 4.9 to 8, 5 to 8, 6 to 8 or 7 to 8 mg.
A range of 8 to 12 mg includes a range of 8.1 to 12, 8.2 to 12, 8.3 to 12, 8.4
to 12,
8.5 to 12, 8.6 to 12, 8.7 to 12, 8.8 to 12, 8.9 to 12, 9 to 12, 10 to 12 or 11
to 12 mg.
No adverse toxicological effects are expected for the compositions or methods
of
the invention in the aforementioned dosage ranges.
-8-
CA 02296653 2000-01-18
WO 99/03477 PCT/GB98/02110
Composition for compound (1)
Preparation of Concentrate: Tabletting concentrate was prepared using the
following
materials
Ingredient Quantity (%)
Milled Compound (I) as maleate 13.25 (pure
salt maleate salt)
Sodium Starch Glycollate 5.00
Hydoxypropyl Methylcellulose 5.00
2910
Microcrystalline Cellulose 20.0
(Avicel PH102)
Lactose Monohydrate, regular to 100
grade
Purified water *
* Removed during processing.
-9-
SUBSTITUTE SHEET (RULE 26)
CA 02296653 2000-01-18
WO 99/03477 PCT/GB98/02110
The concentrate was then formulated into tablets using the following:
Quantity (mg per Tablet)
Tablet Strength 1.0mg 2.0mg 4.0mg 8.0mg
Active Ingredient:
Compound (I) maleate Concentrate granules 10.00 20.00 40.00 80.00
Other Ingredients:
Sodium Starch Glycollate 6.96 6.46 5.46 10.92
Microcrystalline Cellulose (Avicel PH102) 27.85 25.85 21.85 43.70
Lactose monohydrate, (Pharmatose DCL15), 104.44 96.94 81.94 163.88
Magnesium Stearate 0.75 0.75 0.75 1.50
Total Weight of Tablet Core 150.0 150.0 150.0 300.0
Opadry 4.5 4.5 4.5 9.0
Total Weight of Film Coated Tablet 154.5 154.5 154.5 309.0
Compositions for other active agents are as described in the above mentioned
publications.
-10-
SUBSTITUTE SHEET (RULE 26)
